About this Research Topic
Serum therapy involves the administration of purified blood serum from immunized humans or animals (e.g., horses), which contains antibodies, as a form of passive immunization against many diseases and envenomation events. Serum therapy was first introduced in 1890, when Kitasato and von Behring discovered that serum derived from rabbits immunized against diphtheria or tetanus could protect mice exposed to the related pathogens. The authors coined the term antitoxin to describe the administered serum, and designated their treatment as serum therapy. The authors established the principle of serum therapy, based on the evidence that sera from immune animals cured the toxin-exposed ones. As a result, von Behring won the 1901 Nobel Prize in Physiology or Medicine for this research on diphtheria.
To date, the most interesting reported treatment for COVID-19 infection has been the transfusion of passive antibodies from a human survivor of a previous COVID-19 infection; however, serum therapy, as a whole, has not been examined in the current literatures.
We aim to clarify the benefits, cautions, and potential applications of serum therapy in an attempt to facilitate understanding among clinicians.
This Research Topic seeks to share academic achievements among specialists and generalists who may be involved in studies of acute medicine and its clinical practice.
This Research Topic welcomes review articles, original papers, and letters relating to a published issue and/or a particular matter that may be of benefit to the greater readership. Case reports may be published if their clinical or scientific validity is considered significant for publication.
Keywords: serum therapy, neglected tropical disease, antivenom, antitoxin, snake bites, spider bites, toxins, botulinum, clostridium perfringens, diphtheria, tetanus
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.